Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
CHCL (CHCL) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cian Healthcare Limited is a WHO-GMP & ISO-9001:2015 certified company that manufactures a wide range of pharmaceutical, nutraceutical, ayurvedic, cosmeceuticals, sexual wellness, and food supplement products. It operates under various business models including brand business, export, third-party manufacturing, and government supplies. Cian Healthcare has developed over 1,000 formulations and 2,000 brands, indicating significant innovation and breadth in product offerings. The company has licenses and approvals for a wide range of manufacturing services, including tablets and capsules, and conducts chemical, instrumental, and microbiology analysis. Its manufacturing capabilities extend to producing veterinary products for major clients like SAVAvet and Venky's, showcasing its diverse operational scope.
Over the past 52 weeks, CHCL has traded between a low of ₹0.00 and a high of ₹0.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
CHCL has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
CHCL’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of N/A Cr, CHCL is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
CHCL operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of CHCL is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Substantial Acquisition
Reg.29(1) disclosure: Mr. Rajesh Jain, with PACs (Ananta Medicare Ltd and Mr. Pradeep Kumar Jain), reported acquisitions in Cian Healthcare Ltd (BSE-listed) of 52,50,000 and 1,85,00,000 shares, shown as ~21% and ~74% of diluted voting capital.
Substantial Acquisition
Pradeep Kumar Jain, with PACs Ananta Medicare Ltd. and Rajesh Jain, acquired 4,750,000 equity shares of Cian Healthcare Ltd on March 16, 2026 under an NCLT-approved resolution plan (order dated Dec 18, 2025), crossing 5% stake.
Regulatory Filing
Ananta Medicare Limited (acquirer) and PAC Mr. Rajesh Jain submitted a Regulation 29(1) SEBI (SAST) disclosure reporting their acquisition/holding in Cian Healthcare Limited (listed on BSE), citing share counts including 13,750,000 and 10,000,000.
Board Meeting Outcome
Board authorised MD Mr. Rajesh Jain and CS Mr. Rachit Malhotra to determine materiality of events for disclosure and designated Independent Director Mr. Manish Goswami as Chairperson for 1 year effective 16-Mar-2026.
Change in Management
Board of Cian Healthcare appointed Ms. Kalyani Vijay Chordia as Chief Financial Officer (KMP), and Mr. Chirag Mehta as Head‑Operations and Mr. Ravikant Chavan as IT Head, all effective March 16, 2026.
Change in Management
Board of Cian Healthcare appointed Ms. Kalyani Vijay Chordia as Chief Financial Officer (KMP), and Messrs. Chirag Mehta (Head–Operations) and Ravikant Chavan (IT Head), effective March 16, 2026.
Cian Healthcare Limited is a WHO-GMP & ISO-9001:2015 certified company that manufactures a wide range of pharmaceutical, nutraceutical, ayurvedic, cosmeceuticals, sexual wellness, and food supplement products.
It operates under various business models including brand business, export, third-party manufacturing, and government supplies.
Cian Healthcare has developed over 1,000 formulations and 2,000 brands, indicating significant innovation and breadth in product offerings.
The company has licenses and approvals for a wide range of manufacturing services, including tablets and capsules, and conducts chemical, instrumental, and microbiology analysis.
Its manufacturing capabilities extend to producing veterinary products for major clients like SAVAvet and Venky's, showcasing its diverse operational scope.
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
46
Bullish
0
Bearish
0
Neutral
32
Bullish
0
